WO2013128379A2 - Formes polymorphes cristallines de linagliptine - Google Patents

Formes polymorphes cristallines de linagliptine Download PDF

Info

Publication number
WO2013128379A2
WO2013128379A2 PCT/IB2013/051556 IB2013051556W WO2013128379A2 WO 2013128379 A2 WO2013128379 A2 WO 2013128379A2 IB 2013051556 W IB2013051556 W IB 2013051556W WO 2013128379 A2 WO2013128379 A2 WO 2013128379A2
Authority
WO
WIPO (PCT)
Prior art keywords
linagliptin
solution
crystalline
mixture
alcohol
Prior art date
Application number
PCT/IB2013/051556
Other languages
English (en)
Other versions
WO2013128379A3 (fr
Inventor
Srividya Ramakrishnan
Subbareddy Peddireddy
Lalita Kanwar
Original Assignee
Dr. Reddy's Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Limited filed Critical Dr. Reddy's Laboratories Limited
Publication of WO2013128379A2 publication Critical patent/WO2013128379A2/fr
Publication of WO2013128379A3 publication Critical patent/WO2013128379A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present application relates to crystalline polymorphic forms of linagliptin, to processes for preparing them, to pharmaceutical compositions containing them, and to their uses.
  • the drug compound having the adopted name "linagliptin” has chemical names 1 -[(4-Methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-(3-(R)- aminopiperidin-1 -yl) xanthine, or 1 H-purine-2,6-dione, 8-[(3R)-3-amino-1 -piperidinyl]- 7-(2-butyn-1 -yl)-3,7-dihydro-3-methyl-1 -[(4-methyl-2-quinazolinyl)methyl]-; the CAS Registry No. 668270-12-0; I.
  • Linagliptin is a DPP-IV inhibitor and is the active ingredient in a product sold as TRADJENTA®, in the form of 5 mg tablets.
  • U.S. Patent No. 7,407,955 discloses linagliptin, related compounds, and their pharmaceutical compositions. It also describes a process for the preparation of linagliptin, wherein tert-butyloxycarbonyl (Boc)-protected linagliptin is deprotected using 5-6 M isopropanolic hydrochloric acid, followed by purification using chromatography. The patent does not mention the polymorphic form obtained.
  • New polymorphic forms, including solvates, of a pharmaceutical active ingredient can provide materials having desirable processing properties, such as ease of handling, ease of processing, storage stability, and ease of purification, or as desirable intermediate crystal forms that facilitate conversion to other polymorphic forms.
  • New polymorphic forms and solvates of a pharmaceutically useful compound or salts thereof can also provide an opportunity to improve the performance characteristics of a pharmaceutical product.
  • the present application relates to novel polymorphic forms of linagliptin and processes for their preparation.
  • it relates to crystalline Form I and Form II of linagliptin characterized by X-ray powder diffraction ("XRPD”), and processes for their preparation.
  • XRPD X-ray powder diffraction
  • the present application provides crystalline linagliptin Form I characterized by an X-ray powder diffraction pattern comprising peaks at 2-theta angles of about 8.2, 8.9, 20.1 , and 21 .8 ⁇ 0.2. It may be further characterized by XRPD peaks at about 7.1 , 9.8, 10.6, 12.3, 13.5, 14.1 , 14.7, 15.7, 16.8, 19.1 and 19.6
  • the present application provides a process for preparation of crystalline linagliptin Form I, comprising:
  • step a) a) providing a solution of linagliptin in an alcohol or a mixture of alcohols; b) combining water with the solution of step a);
  • the present application provides a process for preparation of crystalline linagliptin Form I, comprising:
  • the present application provides linagliptin crystalline Form II characterized by an XRPD pattern comprising characteristic peaks located at about 4.7, 17.2, and 31 .5, ⁇ 0.2 degrees 2-theta. It may be further characterized by XRPD peaks at about 9.7, 1 1 .7, 15.1 , 18.7, and 22.1 ⁇ 0.2 degrees 2-theta.
  • the present application provides a process for the preparation of linagliptin crystalline Form II, comprising:
  • the present application provides micronized linagliptin Form
  • the present application provides crystalline linagliptin Form I having 90% of particles with particle size less than 300 ⁇ .
  • the present application provides a pharmaceutical composition
  • a pharmaceutical composition comprising the linagliptin Form I and at least one pharmaceutically acceptable excipient.
  • Fig. 1 is an illustrative example of an XRPD pattern of crystalline Form I of linagliptin, prepared in Example 1 .
  • Fig. 2 is an illustrative example of an XRPD pattern of crystalline Form I of linagliptin, prepared in Example 4.
  • Fig. 3 is an illustrative example of an XRPD pattern of crystalline Form II of linagliptin, prepared in Example 14.
  • Fig. 4 is an illustrative example of microscopic image of unmicronized linagliptin crystalline Form I.
  • Fig. 5 is an illustrative example of microscopic image of micronized linagliptin crystalline Form I.
  • aspects of the present application relate to crystalline forms of linagliptin designated herein as Form I and Form II and processes for preparation thereof.
  • Crystalline Form I and Form II of linagliptin may be characterized by any one or more analytical techniques, which may include XRPD patterns, infrared absorption spectra, differential scanning calorimetry (DSC) curves, and thermo gravimetric analysis (TGA) curves.
  • analytical techniques which may include XRPD patterns, infrared absorption spectra, differential scanning calorimetry (DSC) curves, and thermo gravimetric analysis (TGA) curves.
  • Form I a crystalline form of linagliptin, which is designated herein as "Form I.”
  • Form I may be characterized by using one or more analytical methods.
  • crystalline Form I of linagliptin characterized by an XRPD pattern having peaks located substantially in accordance with the pattern shown in Figure 1 .
  • crystalline Form I of linagliptin characterized by X-ray powder diffraction ("XRPD") pattern substantially as shown in Figure 2.
  • the present application provides crystalline Form I of linagliptin characterized by an XRPD pattern comprising characteristic peaks located at about 8.2, 8.9, 20.1 , and 21 .8 ⁇ 0.2 degrees 2-theta. It may be further characterized by XRPD peaks at about 7.1 , 9.8, 10.6, 12.3, 13.5, 14.1 , 14.7, 15.7, 16.8, 19.1 and 19.6 ⁇ 0.2 degrees 2-theta.
  • the present application provides a process for preparation of crystalline Form I of linagliptin, embodiments comprising:
  • Step a) involves providing a solution of linagliptin in an alcohol solvent.
  • the solution of linagliptin may be obtained by dissolving linagliptin in a suitable alcohol solvent, or such a solution may be obtained directly from a chemical synthesis mixture in which linagliptin is formed.
  • Any form of linagliptin is acceptable for forming a solution, such as a crystalline form, an amorphous form, and mixtures thereof.
  • Suitable alcohol solvents that can be used include, but are not limited to, methanol, ethanol, isopropanol, n-butanol, n-propanol, tertiary-butyl alcohol, and the like, including any mixtures thereof.
  • the quantities of solvent used for providing a solution may range from about 3 ml. to about 50 ml_, per gram of linagliptin.
  • the solution may be prepared at any temperatures upto the boiling point of the solvent.
  • the solution may be prepared at ambient temperatures, such as below 35 °C, or in the range of about 0°C to about 30 °C
  • the solution may optionally be treated with activated carbon and then filtered to remove the carbon.
  • the solution may optionally be filtered by passing through paper, glass fiber, or other membrane material, or a bed of a clarifying agent such as Celite®.
  • the filtration apparatus may need to be heated or cooled to avoid undesired crystallization.
  • Step b) involves stirring the solution obtained in step a) to facilitate precipitation.
  • the solution is stirred at temperatures below 30°C.ln embodiments, the solution obtained in step a) is stirred for about 5 minutes to about 20 hours, or longer, at about -20 °C to about 30 °C. In an embodiment the solution of step a) is stirred for about 1 hour to about 10 hours.
  • Step c) involves isolating the solid obtained in step b).
  • the solid may be isolated from the suspension using general techniques known to persons skilled in the art for separating solids from liquids.
  • the solid may be isolated by using techniques such as, for example, filtration by gravity or by suction, centrifugation, decantation, and the like.
  • the solid optionally can be washed with the solvent used in step a) to wash out residual mother liquor.
  • the present application provides a process for preparation of crystalline Form I of linagliptin, embodiments comprising: a) providing a solution of linagliptin in an alcohol solvent or a mixture of alcohol solvents;
  • step b) combining water with the solution of step a);
  • Step a) involves providing a solution of linagliptin in an alcohol solvent or a mixture of alcohol solvents.
  • the solution of linagliptin may be obtained by dissolving linagliptin in a suitable alcohol solvent, or such a solution may be obtained directly from a chemical synthesis mixture in which linagliptin is formed.
  • Suitable alcohol solvents that can be used include, but are not limited to, methanol, ethanol, isopropanol, n-butanol, n-propanol, tertiary-butyl alcohol, and the like, including any mixtures thereof.
  • Suitable mixtures alcohol solvents that can be used include, but are not limited to, a mixture of methanol and ethanol, a mixture of methanol and isopropanol, a mixture of methanol and n-propanol, a mixture of ethanol and isopropanol.
  • the mixture of alcohol solvents may range from about 0.5:9.5 to about 9.5:0.5.
  • the quantities of solvent or a mixture of solvents used for providing a solution may range from about 2 ml. to about 50 ml_, per gram of linagliptin.
  • the solution may be prepared at any temperatures up to the boiling point of the solvent.
  • the solution may be prepared at ambient temperatures, such as below 35 ⁇ , or in the range of about -I CC to about 35 ⁇ .
  • the solution may optionally be treated with activated carbon and then filtered to remove the carbon.
  • the solution may optionally be filtered by passing through paper, glass fiber, or other membrane material, or a bed of a clarifying agent such as Celite®.
  • the filtration apparatus may need to be heated or cooled to avoid undesired crystallization.
  • the solution is stirred at about 0°C. In one embodiment, the solution obtained is stirred for about 5 minutes to about 20 hours, or longer, at about -20 ⁇ to about 30 °C. In an embodiment the solution obtained is stirred for about 30 minutes to about 5 hours.
  • Step b) includes combining water with the solution of a).
  • the quantity of water used may range from about 0.1 ml to about 100 ml, per gram of linagliptin.
  • the addition of water may be done at any temperatures, including about -30°C to about 65 °C.
  • the obtained solution may be seeded with linagliptin Form I crystals.
  • the obtained suspension may be stirred for about 15 minutes to about 20 hours, or longer, to enhance the extent of crystallization.
  • Useful temperatures for maintaining a suspension may range from about -30 °C to about 35 °C.
  • Step c) involves isolating linagliptin Form I obtained in step b).
  • the crystalline linagliptin Form I may be isolated from the suspension using general techniques known to persons skilled in the art for separating solids from liquids.
  • the solid may be isolated by using techniques such as, for example, filtration by gravity or by suction, centrifugation, decantation, and the like. After isolation of the solid, the solid optionally can be washed with the solvent used in step a) to wash out residual mother liquor.
  • the obtained solid of linagliptin may be dried.
  • the drying of solid material may be carried out under suitable conditions to afford the desired crystalline form of linagliptin, substantially free of residual solvents. Drying may be carried out at reduced pressures, such as more than about 500 mm Hg, at temperatures such as about 0°C to about 60°C, or higher. Drying may be suitably carried out using equipment such as a rotary dryer, tray dryer, vacuum oven, air oven, humidity dryer, fluidized bed dryer, spin flash dryer, flash dryer, or combinations thereof.
  • the present application provides a process for reducing residual alcohol in linagliptin Form I to pharmaceutically acceptable level.
  • the process involves contacting said linagliptin Form I with a suitable humidified gas or humidified air under conditions which permit residual alcohol to be entrained in the gas, and removing the solvent and/or gas mixture.
  • a suitable humidified gas or humidified air under conditions which permit residual alcohol to be entrained in the gas, and removing the solvent and/or gas mixture.
  • the humidified gas is passed through a fluidized bed or ANFD or humidity chamber of the linagliptin Form I.
  • the drying of linagliptin Form I can be carried out in a controlled humidity environment having a relative humidity ("RH"), such as below 96% RH, or between about 30 to about 96% RH, at temperatures such as about 0-60 °C. Exposure to a humid environment can reduce the residual solvent content.
  • the humidification drying may be performed for any desired time periods that achieve the desired product purity and residual solvent content, such as times from about 1 hour to about 30 hours, or longer. Drying may also be carried out for shorter or longer periods of time depending on the product specifications.
  • the linagliptin Form I obtained contains about 3 % to about 10% of water by weight, and more preferably about 4% to about 8% of water by weight as determined by KF.
  • the crystalline Form I of linagliptin obtained by processes of the present application may have a polymorphic purity greater than about 95%, or greater than about 98%, or greater than about 98.5%, or greater than about 99%, or greater than about 99.5%.
  • the crystalline Form I of linagliptin obtained by a process of the present application may be utilized for the preparation of an amorphous form, as well as other crystalline polymorphs.
  • the present application provides pharmaceutical formulations comprising crystalline Form I of linagliptin and at least one pharmaceutically acceptable excipient.
  • the crystalline Form I of linagliptin produced according to processes of the present application is useful for making pharmaceutical dosage forms for the treatment of type II diabetes mellitus, prediabetes, i.e., reduced glucose tolerance, and obesity.
  • Form II a crystalline form of linagliptin, which is designated herein as "Form II.”
  • Form II may be characterized by using one or more analytical methods.
  • crystalline Form II of linagliptin characterized by an XRPD pattern having peaks located substantially in accordance with the pattern shown in Figure 3.
  • the present application provides crystalline Form II of linagliptin characterized by an XRPD pattern comprising characteristic peaks located at about 4.7, 17.2, and 31 .5, ⁇ 0.2 degrees 2-theta. It may be further characterized by XRPD peaks at about 9.7, 1 1 .7, 15.1 , 18.7, and 22.1 ⁇ 0.2 degrees 2-theta.
  • the present application provides a process for the preparation of linagliptin crystalline Form II, comprising:
  • Step a) involves providing a solution of linagliptin in an alcohol solvent.
  • the solution of linagliptin may be obtained by dissolving linagliptin in a suitable alcohol solvent, or such a solution may be obtained directly from a chemical synthesis mixture in which linagliptin is formed.
  • Step b) includes combining an anti-solvent with the solution of a).
  • Anti- solvents that may be used for the preparation of linagliptin Form I I include, but are not limited to, ethers such as diethyl ether, diisopropyl ether, methyl tertiary-butyl ether (MTBE), and the like.
  • the quantities of anti-solvent used may range from about 3 ml. to about 50 ml_, per gram of linagliptin.
  • Addition of the anti-solvent may be performed at any temperatures, including about 0°C to about 35 °C.
  • the obtained suspension may be stirred for about 15 minutes to about 20 hours, or longer, to enhance the extent of crystallization.
  • Useful temperatures for maintaining a suspension may range from about -30 °C to about 60 °C.
  • Step c) includes isolating a solid from the mixture of step b).
  • the solid may be isolated from the suspension using general techniques known to persons skilled in the art for separating solids from liquids.
  • the solid may be isolated by using techniques such as, for example, filtration by gravity or by suction, centrifugation, decantation, and the like.
  • the solid may optionally be washed with a suitable solvent such as diethyl ether, diisopropyl ether, MTBE, and the like to wash out residual mother liquor.
  • the crystalline Form II of linagliptin obtained by processes of the present application may have a polymorphic purity greater than about 95%, or greater than about 98%, or greater than about 98.5%, or greater than about 99%, or greater than about 99.5%.
  • the crystalline Form II of linagliptin obtained by processes of the present application may be utilized for the preparation of an amorphous form, as well as other crystalline polymorphs.
  • the present application provides pharmaceutical formulations comprising linagliptin crystalline Form I or linagliptin crystalline Form II or a mixture of linagliptin crystalline Form I and Form II together with at least one pharmaceutically acceptable excipient.
  • the linagliptin crystalline Form I and Form II of the present application are useful for making pharmaceutical dosage forms for the treatment of type II diabetes mellitus, prediabetes, i.e. reduced glucose tolerance, and obesity.
  • the present application also provides micronized linagliptin Form I.
  • Linagliptin Form I is stable upon micronization. Linagliptin is practically insoluble in water (0.01 mg/ml).
  • Micronized linagliptin has significant pharmaceutical advantages. For example micronized linagliptin has a much higher specific surface area (SSA) than the non-micronized form. An increase in the SSA of low aqueous solubility materials may improve therapeutic activity.
  • Micronized linagliptin Form I may be characterized by particle size or specific surface area.
  • the present application provides crystalline linagliptin Form I having particle sizes less than about 300 ⁇ , preferably less than about 200 ⁇ , more preferably less than about 100 ⁇ , most preferably less than about 50 ⁇ , and still moost preferably less than about 20 ⁇ .
  • Micronized linagliptin Form I may be characterized by its particle size. Preferably at least about 90% micronized linagliptin particles have a particle size of less than about 100 microns, more preferably less than about 50 microns, and most preferably less than about 20 microns.
  • Particle size distributions of linagliptin particles may be measured by any technique known in the art.
  • particle size distributions of linagliptin Form I particles may be measured using light scattering equipment, such as, for example, a Malvern Master Sizer 2000 from Malvern Instruments Limited, Malvern, Worcestershire, United Kingdom (helium neon laser source, linagliptin suspended in light liquid paraffin, size range: 0.01 ⁇ to 3000 ⁇ ).
  • Sample Preparation Transferred about 200 mg of linagliptin Form I sample into a 30 mL stoppered test tube and added 20 mL of dispersant and 2-3 drops of Span 8.5. Then the mixture was kept on cyclomixture for one minute and sonicated for 15 seconds.
  • Another aspect of the present application provides pharmaceutical compositions comprising crystalline Form I and/or Form II of linagliptin, together with one or more pharmaceutically acceptable excipients.
  • the pharmaceutical composition comprising crystalline Form I and/or Form II of linagliptin with a pharmaceutically acceptable carrier may be formulated into solid oral dosage forms such as, but not limited to, powders, granules, pellets, tablets, and capsules; liquid oral dosage forms such as but not limited to syrups, suspensions, dispersions, and emulsions; and injectable preparations such as but not limited to solutions, dispersions, and freeze dried compositions.
  • Formulations may be in the forms of immediate release, delayed release, modified release, and any combinations thereof.
  • immediate release compositions may be conventional, dispersible, chewable, mouth dissolving, or flash melt preparations
  • modified release compositions may comprise hydrophilic or hydrophobic, or combinations of hydrophilic and hydrophobic, release rate controlling substances to form matrix, reservoir, or combinations of matrix and reservoir systems.
  • the compositions may be prepared using any of techniques such as direct blending, dry granulation or wet granulation, or by extrusion and spheronization.
  • Compositions may be presented as uncoated, film coated, sugar coated, powder coated, enteric coated, or modified release coated.
  • compositions that are useful include, but are not limited to, any one or more of: diluents such as starch, pregelatinized starch, lactose, powdered cellulose, microcrystalline cellulose, dicalcium phosphate, tricalcium phosphate, mannitol, sorbitol, sugar, and the like; binders such as acacia, guar gum, tragacanth, gelatin, polyvinylpyrrolidones, hydroxypropyl celluloses, hydroxypropylmethylcelluloses, pregelatinized starches, and the like; disintegrants such as starches, sodium starch glycolate, pregelatinized starches, crospovidones, croscarmellose sodium, colloidal silicon dioxide, and the like; lubricants such as stearic acid, magnesium stearate, zinc stearate, and the like; glidants such as colloidal silicon dioxide and the like; solubility or wetting enhancers such as anionic,
  • linagliptin is a useful active ingredient in the range of about 1 mg to about 50 mg, per dosage unit.
  • PXRD Powder X-ray Diffraction
  • Linagliptin (6.0 g) and ethanol (120 mL) were placed into a 250 mL round bottom flask, heated to 78°C, and stirred for 30 minutes. The clear solution was filtered and the filtrate was placed into a round bottom flask and the solution was cooled to 25 °C and rapidly cooled to -10 ° and maintained for 30 minutes at -10 *0 to 0*0. The precipitate that formed was filtered and the wet solid was suction dried, to afford linagliptin Form I.
  • Linagliptin (2 g) and ethanol (40 mL) were placed into a 100 mL round bottom flask, heated to 78°C, and stirred for 30 minutes. The clear solution was filtered and the filtrate was placed into a round bottom flask and the solution was cooled to 25 ⁇ and maintained for 1 hour at 25 °C. The precipitate that formed was filtered and the wet solid was suction dried, and the material was dried in a vacuum tray drier at 40 °C to afford linagliptin Form I.
  • Linagliptin (10 g) and ethanol (200 mL) were placed into a 500 mL round bottom flask, heated to 79°C, and stirred for 30 minutes. The clear solution was filtered and the filtrate was placed into a round bottom flask and the solution was cooled to -5 to -10*0 and maintained for 1 .5 hours at -5 to -I CC. The precipitate that formed was filtered and the wet solid was suction dried, and the material was dried in a vacuum tray drier at 40*0 for 4hrs to afford linagliptin Form I.
  • PXRD pattern is same as Fig. 1 .
  • Linagliptin (2 g) and a 1 :1 mixture of methanol and isopropanol (40 mL) were placed into a round bottom flask, heated to 56°C, and stirred for about 30 minutes.
  • the clear solution was filtered and the filtrate was placed into a round bottom flask and the solution was seeded with linagliptin Form I crystals (0.1 g) at room temperature, gradually cooled to C and maintained for 2 hours at 0°C.
  • the precipitate that formed was filtered and the wet solid was suction dried, and the material was dried in a vacuum tray drier at 40 °C for 4hrs to afford linagliptin Form I.
  • PXRD pattern Fig. 2
  • Linagliptin (3 g) was suspended in methanol (30 mL) at 25 °C. The mixture was heated to 55°C and stirred for 30 minutes at 55°C. The clear solution was filtered and the filtrate was cooled to 27°C, linagliptin Form I crystals (150 mg) were added, and the mixture was gradually cooled to 5°C over a period of 30 minutes and stirred for 1 hour at 5°C. The suspension was filtered and suction dried for about 10 minutes to obtain a solid. The solid was dried in a vacuum tray drier at 40 °C for about 4 hours in a vacuum tray dryer, to afford linagliptin Form I.
  • Linagliptin (2 g) and a 1 :1 mixture of methanol and isopropanol (40 mL) were placed into a round bottom flask, heated to 50°C, and stirred for about 30 minutes.
  • the clear solution was filtered and the filtrate was placed into a round bottom flask and the solution was charged with water (0.3 mL) and linagliptin Form I crystals (0.1 g).
  • the obtained solution was stirred for 1 hour at 25 °C.
  • the mixture was gradually cooled to 0°C and maintained for 1 hour at 0°C.
  • the precipitate that formed was filtered and the wet solid was suction dried.
  • the solid was dried in a vacuum tray drier at 40 °C for about 4 hours in a vacuum tray dryer, to afford linagliptin Form I.
  • PXRD pattern is same as Fig. 2.
  • Linagliptin (1 g) was suspended in mixture of isopropanol and water (29 mL of Isopropanol and 1 ml of water) at 25 *0. The mixture was heated to 60-65 °C and stirred for 30 minutes at 60-65 °C. The clear solution was filtered and the filtrate was placed into a round bottom flask and cooled to 28*0, then linagliptin Form I crystals (0.3 mg) seeded. The mixture was cooled to 0 *0 within 15 minutes and maintained for 2 hour at 0*0. The precipitate that formed was filtered and the wet solid was suction dried. The solid was dried in a vacuum tray drier at 40 °C for 3 hours in a vacuum tray dryer, to afford linagliptin Form I.
  • Linagliptin (3 g) was suspended in mixture of isopropanol and water (58.8 mL of Isopropanol and 1 .2 mL of water) at 25 ⁇ ., heated to 65°C, and stirred for about 30 minutes. The clear solution was filtered and the filtrate was placed into a round bottom flask and the solution was charged with linagliptin Form I crystals (150 mg), gradually cooled to I CC over a period of 1 hour and further cooled to 0°C in 30 minutes and maintained for 1 hour at 0°C. The precipitate that formed was filtered and the wet solid was suction dried, to afford linagliptin Form I.
  • Linagliptin (30 g) was suspended in methanol (150 mL) at 25*0. The mixture was heated to 55 °C and the clear solution that formed was filtered and the filtrate was cooled to 25*0, water (7.5 mL) was added and seeded with linagliptin Form I crystals (150 mg), and the mixture was stirred for 1 hour at 27°C. The suspension was cooled to 0 *0 and stirred for 1 hour at 0*0. The suspension was filtered and suction dried for about 10 minutes to afford linagliptin Form I.
  • Linagliptin (100 g) was suspended in methanol (500 mL) at 25 °C. The mixture was heated to 54 °C and the clear solution that formed was filtered and the filtrate was cooled to 35 ⁇ , water (25 mL) was added and seeded with linagliptin Form I crystals (5 g), and the mixture was stirred for 1 hour at 30 'C. The suspension was cooled to 0°C and stirred for 1 hour at 0°C. The suspension was filtered and suction dried for about 10 minutes and the wet material was dried in a vacuum tray drier at 40°C mmHg for 8 hours to afford Linagliptin Form I. OVI (Methanol): 10253 ppm.
  • the dry material was humidified at 40 °C and 75%RH for 6 hours. Then the humidified material was dried in a vacuum tray drier at 40°C and 690 mmHg for 8 hours and checked for methanol content.
  • Linagliptin (80 g) was suspended in methanol (200 mL) at 25°C. The mixture was heated to 60 °C and the clear solution that formed was filtered and the filtrate was cooled to 35°C, water (200 mL) was added and seeded with linagliptin Form I crystals (4 g), and the mixture was stirred for 1 hour at 30 'C. The suspension was cooled to 0°C and stirred for 1 hour at 0°C. The suspension was filtered and suction dried for about 10 minutes and the wet material was dried in a vacuum tray drier at 40 °C and 650 mmHg for 3 hours and checked for methanol content. OVI (Methanol): 6000 ppm.
  • the material was humidified at 40*0 and 75%RH for 4 hours. Then the humidified material was dried in a vacuum tray drier at 40°C and 690 mmHg for 4 hours to afford Linagliptin Form I.
  • OVI Methanol: 1500 ppm; Moisture content: 7.32%.
  • Linagliptin (40 g) was suspended in methanol (200 mL) at 25*0. The mixture was heated to 58 °C and the clear solution that formed was filtered and the filtrate was cooled to 35*0, water (10 mL) was added and seeded with linagliptin Form I crystals (2 g), and the mixture was stirred for 1 hour at 30 *0. The suspension was cooled to 0°C and stirred for 1 hour at 0*0. The suspension was filtered and suction dried for about 10 minutes to yield 40 g of wet linagliptin Form I. OVI (Methanol): 27876 ppm.
  • EXAMPLE 14 PREPARATION OF LINAGLIPTIN CRYSTALLINE FORM II.
  • Linagliptin (4 g) was suspended in methanol (20 mL) at 25 °C. The mixture was heated to 65 °C and stirred for 1 hour at 65 °C. The clear solution that formed was filtered through a Celite® bed, and the filtrate was placed into a round bottom flask and was cooled to 30°C. Methyl tertiary-butyl ether (40 mL) was added over 10 minutes, and the mixture was stirred for about 1 hour at 28 °C. The suspension was filtered and suction dried for about 10 minutes to obtain a solid. The solid was dried at 40 °C for about 4 hours in a vacuum tray dryer (VTD), to afford linagliptin Form II.
  • PXRD pattern Fig. 3; TGA weight loss: 9.1 %; Moisture: 8.9%; Methanol: 410 ppm; methyl tertiary-butyl ether: 1805 ppm.
  • EXAMPLE 15 PREPARATION OF LINAGLIPTIN CRYSTALLINE FORM II.
  • Linagliptin (2 g) was suspended in methanol (10 mL) at 25 °C. The mixture was heated to 65 °C and stirred for 1 hour at 45°C. The clear solution that formed was filtered through a Celite® bed, and the filtrate was placed into a round bottom flask and was cooled to 28 °C. Methyl tertiary-butyl ether (20 mL) was added over 10 minutes, and the mixture was stirred for about 1 hour at 28*0. The suspension was filtered and suction dried for about 10 minutes to obtain a solid. The solid was dried at 40°C for about 4 hours in a vacuum tray dryer, to afford linagliptin Form II.
  • PXRD pattern Fig. 3; TGA weight loss: 7.1 %; Moisture: 6.1 %: Methanol: 452 ppm; methyl tertiary-butyl ether: 4138 ppm.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente demande concerne des polymorphes cristallins de linagliptine et des procédés pour les préparer. En outre, la présente demande concerne l'utilisation des nouveaux polymorphes de linagliptine pour la préparation d'un médicament, et des compositions pharmaceutiques comprenant une quantité efficace des polymorphes cristallins de linagliptine.
PCT/IB2013/051556 2012-02-27 2013-02-27 Formes polymorphes cristallines de linagliptine WO2013128379A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
IN723/CHE/2012 2012-02-27
IN723CH2012 2012-02-27
IN3401/CHE/2012 2012-08-17
IN3401CH2012 2012-08-17
IN5356/CHE/2012 2012-12-21
IN5356CH2012 2012-12-21

Publications (2)

Publication Number Publication Date
WO2013128379A2 true WO2013128379A2 (fr) 2013-09-06
WO2013128379A3 WO2013128379A3 (fr) 2013-10-31

Family

ID=49083398

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/051556 WO2013128379A2 (fr) 2012-02-27 2013-02-27 Formes polymorphes cristallines de linagliptine

Country Status (1)

Country Link
WO (1) WO2013128379A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017047970A1 (fr) * 2015-09-17 2017-03-23 한미정밀화학주식회사 Forme cristalline de linagliptine et procédé de préparation de cette dernière
CN109111443A (zh) * 2018-08-28 2019-01-01 上海迪赛诺药业股份有限公司 Dpp-iv抑制剂类降糖药的新晶型及其制备方法
CN109748919A (zh) * 2017-11-07 2019-05-14 四川科伦药物研究院有限公司 一种利格列汀的晶型及其制备方法
CN110305131A (zh) * 2019-07-03 2019-10-08 山东百诺医药股份有限公司 利格列汀新晶型及其制备方法
WO2019203755A2 (fr) 2017-12-15 2019-10-24 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Forme pharmaceutique orale solide comprenant de la linagliptine
CN113754664A (zh) * 2021-09-23 2021-12-07 山东罗欣药业集团股份有限公司 一种利格列汀晶型及其制备方法
WO2021250995A1 (fr) * 2020-06-10 2021-12-16 有機合成薬品工業株式会社 Morphologie cristalline de 1- [(4-méthyl-quinazoline-2-yl)méthyl]-3-méthyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-péperidine-1-yl)-xanthine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007128721A1 (fr) * 2006-05-04 2007-11-15 Boehringer Ingelheim Internationalgmbh Polymorphes
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2007128721A1 (fr) * 2006-05-04 2007-11-15 Boehringer Ingelheim Internationalgmbh Polymorphes

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170033684A (ko) 2015-09-17 2017-03-27 한미정밀화학주식회사 리나글립틴 결정형 및 이의 제조방법
CN108290891A (zh) * 2015-09-17 2018-07-17 韩美精密化学株式会社 一种利格列汀晶型及其制备方法
WO2017047970A1 (fr) * 2015-09-17 2017-03-23 한미정밀화학주식회사 Forme cristalline de linagliptine et procédé de préparation de cette dernière
CN109748919A (zh) * 2017-11-07 2019-05-14 四川科伦药物研究院有限公司 一种利格列汀的晶型及其制备方法
WO2019203755A2 (fr) 2017-12-15 2019-10-24 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Forme pharmaceutique orale solide comprenant de la linagliptine
CN109111443A (zh) * 2018-08-28 2019-01-01 上海迪赛诺药业股份有限公司 Dpp-iv抑制剂类降糖药的新晶型及其制备方法
WO2020042939A1 (fr) * 2018-08-28 2020-03-05 上海迪赛诺药业股份有限公司 Nouvelle forme cristalline d'un médicament hypoglycémique inhibiteur de dpp-iv et son procédé de préparation
JP2021535218A (ja) * 2018-08-28 2021-12-16 シャンハイ ディサノ ファーマシューティカルズ インベストメント カンパニー リミテッドShanghai Desano Pharmaceuticals Investment Co., Ltd. Ｄｐｐ−ｉｖ阻害剤の血糖降下薬の新しい結晶形およびその調製方法
CN110305131A (zh) * 2019-07-03 2019-10-08 山东百诺医药股份有限公司 利格列汀新晶型及其制备方法
CN110305131B (zh) * 2019-07-03 2021-12-31 山东百诺医药股份有限公司 利格列汀新晶型及其制备方法
WO2021250995A1 (fr) * 2020-06-10 2021-12-16 有機合成薬品工業株式会社 Morphologie cristalline de 1- [(4-méthyl-quinazoline-2-yl)méthyl]-3-méthyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-péperidine-1-yl)-xanthine
WO2021251467A1 (fr) * 2020-06-10 2021-12-16 有機合成薬品工業株式会社 Morphologie cristalline de 1-[(4-méthyl-quinazoline-2-yl)méthyl]-3-méthyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-pipéridine-1-yl)-xanthine
CN113754664A (zh) * 2021-09-23 2021-12-07 山东罗欣药业集团股份有限公司 一种利格列汀晶型及其制备方法
CN113754664B (zh) * 2021-09-23 2022-08-16 山东罗欣药业集团股份有限公司 一种利格列汀晶型及其制备方法

Also Published As

Publication number Publication date
WO2013128379A3 (fr) 2013-10-31

Similar Documents

Publication Publication Date Title
WO2013128379A2 (fr) Formes polymorphes cristallines de linagliptine
KR100376074B1 (ko) 구아닌유도체
CN106414466B (zh) 替诺福韦艾拉酚胺复合物及其制备方法和用途
JP6591759B2 (ja) ナルメフェン塩酸塩二水和物
EP2262768A2 (fr) Préparation de lénalidomide
EP2989084A1 (fr) Modifications cristallines d'élobixibat
WO2011158248A2 (fr) Procédé pour la préparation de posaconazole et forme polymorphique cristalline v de posaconazole
AU2021276912B2 (en) Crystalline form of LNP023
WO2016027243A1 (fr) Nouvelles formes solides de dimaléate d'afatinib
US20150051228A1 (en) Amorphous form of linagliptin and process for preparation thereof
CN110582497A (zh) 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的晶型及其制备方法和药物组合物
DK2370440T3 (en) 8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dion2-amino-2- (hydroxymethyl) -1,3-propandiolanhydrat for the treatment of diseases
US20090306106A1 (en) Forms of crystalline lapatinib and processes for preparation thereof
JP2019031524A (ja) ナルメフェン塩酸塩二水和物
JP6594325B2 (ja) 臭化チオトロピウムとラクトースの結晶形態
WO2017032705A1 (fr) Forme cristalline d'omarigliptine
WO2011095984A1 (fr) Procédé de préparation d'ésoméprazole amorphe
CN117561248A (zh) 伊沃替尼和其盐的晶型及其制备方法和用途
EP4085062A1 (fr) Nouveaux sels et/ou co-cristaux de ténofovir alafénamide
CN101607960B (zh) 醋茶溴索及其组合物
CN112300119A (zh) 美利曲辛与氟哌噻吨共晶及其制备方法
WO2009003001A2 (fr) Préparation d'hémi-pentahydrate de risédronate de sodium
MXPA97005462A (en) Derived from guan

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13754427

Country of ref document: EP

Kind code of ref document: A2